Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
ConclusionsSAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Autoimmune Disease | Brain | Finland Health | Multiple Sclerosis | Neurology | Pneumonia | Study